Edition:
United States

ZELTIQ Aesthetics Inc (ZLTQ.OQ)

ZLTQ.OQ on NASDAQ Stock Exchange Global Select Market

55.78USD
27 Mar 2017
Change (% chg)

$-0.02 (-0.04%)
Prev Close
$55.80
Open
$55.71
Day's High
$55.83
Day's Low
$55.62
Volume
165,048
Avg. Vol
321,592
52-wk High
$56.17
52-wk Low
$23.60

ZLTQ.OQ

Chart for ZLTQ.OQ

About

ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $2,251.91
Shares Outstanding(Mil.): 40.36
Dividend: --
Yield (%): --

Financials

  ZLTQ.OQ Industry Sector
P/E (TTM): 4,716.82 47.84 29.94
EPS (TTM): -0.03 -- --
ROI: 0.52 6.88 13.01
ROE: 0.53 10.85 14.16

BRIEF-Zeltiq Aesthetics posts Q4 profit of $0.25/share

* Zeltiq announces fourth quarter and full year 2016 financial results

Mar 01 2017

Allergan to buy fat-fighter Zeltiq Aesthetics for $2.48 billion

Botox maker Allergan Plc <AGN.N,> agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.

Feb 13 2017

CORRECTED-UPDATE 2-Allergan to buy Zeltiq Aesthetics for about $2.48 bln

Feb 13 Botox maker Allergan Plc said it would buy body-contouring product maker Zeltiq Aesthetics Inc for about $2.48 billion, adding muscle to its line-up of products used to fight fat and smoothen wrinkles.

Feb 13 2017

BRIEF-Allergan agrees to acquire Zeltiq for $2.48 bln

* Allergan has agreed to acquire Zeltiq for $56.50 per share, or $2.475 billion

Feb 13 2017

Allergan agrees to buy Zeltiq for about $2.48 bln

Feb 13 Allergan Plc on Monday said it would buy Zeltiq Aesthetics Inc for about $2.48 billion to gain access to its flagship body contouring technology.

Feb 13 2017

BRIEF-ZELTIQ Aesthetics reports Q3 earnings per share $0.12

* Sees FY 2016 adjusted EBITDA margin of approximately 8% of total revenue, compared to prior guidance of 7% to 9%

Nov 09 2016

More From Around the Web

Competitors

  Price Chg
Cutera, Inc. (CUTR.OQ) $20.25 +0.10
Bruker Corporation (BRKR.OQ) $22.73 -0.46
PerkinElmer, Inc. (PKI.N) $58.03 +0.51
Intuitive Surgical, Inc. (ISRG.OQ) $767.32 +9.32
C R Bard Inc (BCR.N) $250.78 +0.87

Earnings vs. Estimates